I Spier
Overview
Explore the profile of I Spier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
28
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Spier I, Huneburg R, Aretz S
Internist (Berl)
. 2020 Nov;
62(2):133-144.
PMID: 33237439
Background: Gastrointestinal polyposis syndromes are the second most common cause of hereditary colorectal carcinomas after Lynch syndrome (hereditary non-polyposis colon cancer, HNPCC). The detection of a causal germline mutation in...
2.
Huneburg R, Heling D, Kaczmarek D, van Heteren P, Olthaus M, Fimmers R, et al.
Endosc Int Open
. 2020 Oct;
8(10):E1308-E1314.
PMID: 33015332
Duodenal cancer is the cancer most often seen in patients with familial adenomatous polyposis (FAP) who have undergone risk-reducing colonic surgery. Almost all patients with FAP eventually develop duodenal adenomas...
3.
Maier P, Heckmann D, Spier I, Laufs S, Zucknick M, Allgayer H, et al.
Cancer Gene Ther
. 2012 Oct;
19(11):802-10.
PMID: 23037811
Chemoprotection of haematopoietic stem cells (HSCs) by gene therapeutic transfer of drug-resistance genes represents the encouraging approach to prevent myelosuppression, which is one of the most severe side effects in...
4.
Spier I, Aretz S
Internist (Berl)
. 2012 Mar;
53(4):371-2, 374-6, 378-80 passim.
PMID: 22430643
Hereditary gastrointestinal polyposis syndromes account for around 1% of all colorectal cancers; most of them are associated with a broad spectrum of extracolonic tumors. The initial diagnosis is based on...
5.
Maier P, Spier I, Laufs S, Veldwijk M, Fruehauf S, Wenz F, et al.
Gene Ther
. 2009 Oct;
17(3):389-99.
PMID: 19865182
Myelotoxicity is a dose-limiting effect of many chemotherapeutic regimens. Thus, there is great interest in protecting human hematopoietic stem cells by the transfer of drug resistance genes. The main focus...
6.
Eizirik C, de Abreu P, da Fonseca A, Caleffi L, Rocha D, Spier I, et al.
Educ Med Salud
. 1990 Oct;
24(4):424-39.
PMID: 2090455
No abstract available.